What is the appropriate treatment plan for a patient with grade 3 chondromalacia of the glenoid?

Treatment of Grade 3 Chondromalacia of the Glenoid

Begin with a 3-6 month trial of conservative management including physical therapy and consider intra-articular corticosteroid injections, progressing to total shoulder arthroplasty (TSA) over hemiarthroplasty if conservative measures fail and symptoms significantly impair quality of life.

Initial Conservative Management (First-Line)

Start all patients with grade 3 glenoid chondromalacia on conservative treatment for 3-6 months before considering surgical intervention 1. This approach is standard despite limited high-quality evidence specifically for shoulder cartilage defects 2.

Conservative Treatment Components:

• Physical therapy: Focus on rotator cuff strengthening, scapular stabilization, and range of motion exercises
• Intra-articular corticosteroid injections: While AAOS guidelines state they "are unable to recommend for or against" due to lack of shoulder-specific evidence (Grade I recommendation), these injections are widely used in clinical practice and may provide symptomatic relief 1
• Viscosupplementation: This is a weak option (Grade C) based on limited industry-supported evidence showing improvements in pain and function scores at 1,3, and 6 months 1

Important caveat: The evidence for injectable treatments in the shoulder is extrapolated primarily from hip and knee literature, as shoulder-specific data remains limited 1.

Surgical Management (When Conservative Treatment Fails)

For Patients ≥50 Years Old:

Total shoulder arthroplasty (TSA) is superior to hemiarthroplasty and represents the only moderate-strength recommendation in the AAOS guidelines 1. TSA provides significant improvements in pain, function, and quality-of-life scores compared to hemiarthroplasty.

Critical Contraindications:

• Do not perform TSA in patients with irreparable rotator cuff tears (consensus recommendation) 1
• Avoid surgeons performing fewer than 2 shoulder arthroplasties per year due to increased risk of immediate postoperative complications (Grade C recommendation) 1

For Patients <50 Years Old:

This population presents a significant challenge. Concern exists about performing shoulder arthroplasty in patients aged <50 years due to increased risk of prosthetic loosening and decreased survivorship 1.

Consider arthroscopic options, though evidence is inconclusive:

• Arthroscopic debridement: Grade I recommendation (unable to recommend for or against) 1
• Microfracture: No shoulder-specific data, but emerging evidence from hip studies shows promise when augmented with allograft cartilage and platelet-rich plasma 3
• Osteochondral autograft/allograft transplantation: Limited evidence available 2

Surgical Algorithm:

1. Age ≥50 years + intact rotator cuff + failed conservative treatment → TSA (preferred over hemiarthroplasty)
2. Age <50 years + failed conservative treatment → Consider arthroscopic debridement or microfracture, but counsel patients that evidence is limited
3. Any age + irreparable rotator cuff tear → TSA is contraindicated; consider hemiarthroplasty or reverse shoulder arthroplasty (though not specifically addressed for this indication)

Common Pitfalls to Avoid:

• Do not rush to surgery: Most treatments for glenohumeral osteoarthritis lack strong evidence, making adequate conservative trials essential 1
• Do not perform TSA with irreparable rotator cuff tears: This is a consensus contraindication 1
• Do not refer to low-volume surgeons: Surgeon experience matters for outcomes 1
• Do not assume arthroscopic treatments work: The evidence is inconclusive (Grade I), despite their appeal in younger patients 1

Evidence Quality Note:

The AAOS guideline acknowledges that 9 of 16 recommendations are inconclusive, reflecting the poor quality of evidence in this field 1. Management remains controversial, and clinical decisions must weigh limited evidence against patient-specific factors including age, symptom severity, functional demands, and willingness to accept surgical risks.